cas 6223-78-5|| where to buy 2,5-Dichloro-2,5-dimethylhexane

Produktname:2,5-Dichloro-2,5-dimethylhexane

IUPAC Name:2,5-dichloro-2,5-dimethylhexane

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM361084-100g	in stock	Ťħ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 6223-78-5 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:6223-78-5; Molekulare Formel:C8H16Cl2; Schmelzpunkt:-; SMILES-Code:CC(C)(Cl)CCC(C)(Cl)C; Dichte:

: Katalognummer:CM361084; Molekulargewicht:183.12; Siedepunkt:; Mdl-Nr.:MFCD00126854; Lagerung:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Palovarotene; A breakthrough treatment raises hopes for rare bone disease. Palovarotene (Sohonos) has been recently approved by the FDA as a retinoid indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare progressive genetic disease effecting one in a million individuals. This first and only treatment is able to effectively reduce the formation of new abnormal bone in soft and connective tissues.